STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALNY
  4. [Form 4] ALNYLAM PHARMACEUTICALS, INC. Insider Trading Activity

Alnylam (ALNY) director Olivier Brandicourt receives new RSU and option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ALNYLAM PHARMACEUTICALS, INC. director Olivier Brandicourt reported compensation-related equity awards, not open-market trades. He received 671 shares of common stock in the form of restricted stock units granted at no cash cost.

Brandicourt was also granted stock options for 1,441 shares of common stock at an exercise price of $298.48 per share. Both the RSUs and the options vest in full on the earlier of the first anniversary of the May 20, 2026 grant date or his earlier retirement or resignation, if that occurs no more than 90 days before the first anniversary. Following these awards, he directly holds 1,446 common shares and 1,441 stock options.

Positive

  • None.

Negative

  • None.
Insider BRANDICOURT OLIVIER
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 1,441 $0.00 --
Grant/Award Common Stock 671 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 1,441 shares (Direct, null); Common Stock — 1,446 shares (Direct, null)
Footnotes (1)
  1. These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
RSU grant 671 shares Restricted stock units granted May 20, 2026
Option grant size 1,441 options Stock options for common stock granted May 20, 2026
Option exercise price $298.48/share Conversion or exercise price for 1,441 stock options
Shares after grant 1,446 shares Common stock directly held after RSU award
Option expiration May 20, 2036 Expiration date of stock options
restricted stock units (RSUs) financial
"These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Second Amended and Restated 2018 Stock Incentive Plan financial
"RSUs granted under the Second Amended and Restated 2018 Stock Incentive Plan."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 298.4800."
exercise price financial
"conversion_or_exercise_price: "298.4800" for the stock option grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BRANDICOURT OLIVIER
(Last)(First)(Middle)
675 WEST KENDALL STREET
(Street)
CAMBRIDGE MASSACHUSETTS 02142
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/20/2026A671(1)A$01,446D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$298.4805/20/2026A1,44105/20/2027(2)05/20/2036Common Stock1,441$01,441D
Explanation of Responses:
1. These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
2. The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
Brett Budzinski, Attorney-in-Fact For: Olivier Brandicourt05/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ALNY director Olivier Brandicourt report?

Olivier Brandicourt reported equity awards, not market trades. He received 671 restricted stock units and stock options for 1,441 shares, both granted on May 20, 2026 as part of his director compensation package.

How many ALNY shares did Olivier Brandicourt receive through RSUs?

He received 671 restricted stock units, each representing one share of ALNY common stock. These RSUs vest in full on the first anniversary of the May 20, 2026 grant or certain earlier retirement or resignation conditions.

What are the terms of Olivier Brandicourt’s ALNY stock options?

Brandicourt was granted options on 1,441 ALNY shares at an exercise price of $298.48. The options vest fully on the first anniversary of the May 20, 2026 grant date or earlier qualifying retirement or resignation, and expire on May 20, 2036.

When do Olivier Brandicourt’s ALNY RSUs and options vest?

Both the 671 RSUs and 1,441 stock options vest in full on the earlier of the first anniversary of the May 20, 2026 grant date or the date of his retirement or resignation, if that occurs within 90 days before that anniversary.

How many ALNY shares does Olivier Brandicourt hold after these awards?

After the May 20, 2026 awards, Brandicourt directly holds 1,446 shares of ALNY common stock. He also holds stock options covering 1,441 shares, which are exercisable at $298.48 per share once vested.

Are Olivier Brandicourt’s ALNY equity awards open-market purchases or sales?

They are not open-market trades. The Form 4 shows compensation-related grants: 671 restricted stock units and 1,441 stock options, both awarded at a grant price of $0.00, with a separate $298.48 exercise price for the options.